BEHAVIOR OF LIPID NANOCAPSULES AFTER ORAL ADMINISTRATION
Résumé
The oral route is the most common route for drug delivery. However, some drugs present a low oral bioavailability due to low drug solubility, drug degradation along the gastrointestinal tract, or low intestinal permeability. To improve oral drug delivery, drug encapsulation into nanocarriers, such as lipid nanocapsules (LNCs), is currently one of the most promising technologies. LNCs, developed by our group, have proven to be very interesting for oral administration. These nanoparticles have a size that ranges from 20 to 130 nm and are prepared by a well-known low-energy emulsification process: the phase-inversion temperature method. They have already shown promising properties for the oral delivery of paclitaxel, Sn38, fondaparinux, decitabine, and miltefosine. However, despite the promising benefits, these studies focus only on monitoring drugs encapsulated in nanocarrier but ignore the performance of the nanocarrier itself.
Currently, the only method that can characterize the particle integrity of organic nanoparticles is by Förster resonance energy transfer (FRET). It is a subset of the fluorescence technique often dubbed the ‘nano-ruler’ since the technique is very sensitive to the distance change in nanoscale and is thus proved to be useful for monitoring the association or the dissociation of organic nanoparticles. In this context, FRET-LNCs were developed and the behavior of LNC after oral administration was studied. This lecture will try to explain how LNCs allow for enhancing the oral bioavailability of drugs. Special attention will be paid to the ability of those LNCs to maintain their full integrity using in vitro and in vivo models.
Domaines
Pharmacie galénique
Origine : Fichiers produits par l'(les) auteur(s)